Mode
Text Size
Log in / Sign up
Phase 1 N=66 Randomized Double-blind Treatment

SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects

Eosinophilic Esophagitis (EoE)

Enrolled (actual)
66
Serious AEs
0.0%
Results posted
Dec 2024
Primary outcome: Primary: Part A (SAD): Number of Treatment Emergent Adverse Events (TEAEs) by Participant — 1; 0; 1; 2 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 1
Interventions
AQ280 (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
AQILION AB
Primary completion
Jul 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Part A (SAD): Number of Treatment Emergent Adverse Events (TEAEs) by Participant
1; 0; 1; 2; 1; 2
PRIMARY
Part A (SAD): Number of Treatment Emergent Adverse Events (TEAEs) Experienced
1; 0; 1; 2; 2; 3
PRIMARY
Part B (MAD): Number of Treatment Emergent Adverse Events (TEAEs) by Participant
3; 3; 3; 3
PRIMARY
Part B (MAD): Number of Treatment Emergent Adverse Events (TEAEs) Experienced
7; 6; 8; 4
PRIMARY
Part A (SAD): Number of Participants With Clinically Significant Abnormalities in Vital Signs
0; 0; 0; 0; 0; 0
PRIMARY
Part A (SAD): Number of Participants With Abnormal ECG
0; 0; 0; 0; 0; 0
PRIMARY
Part A (SAD): Number of Subjects With Clinically Significant Changes in Laboratory Evaluations
0; 0; 0; 0; 0; 0
PRIMARY
Part B (MAD): Number of Participants With Clinically Significant Abnormalities in Vital Signs
0; 0; 0; 0
PRIMARY
Part B (MAD): Number of Participants With Abnormal ECG
0; 0; 0; 0
PRIMARY
Part B (MAD): Number of Participants With Clinically Significant Changes in Laboratory Evaluations
0; 0; 0; 1; 0; 0
SECONDARY
Part A (SAD) - Primary PK Parameters Derived From Plasma Concentration-time Profile of AQ280: Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity
77.0; 318; 539; 527; 1860; 2820 0.6358
SECONDARY
Part A (SAD) - Primary PK Parameter Derived From Plasma Concentration-time Profile of AQ280: Maximum Observed Concentration (Cmax)
20.0; 70.1; 113; 90.8; 418; 638 0.3653
SECONDARY
Part A (SAD) - Primary PK Parameter Derived From Plasma Concentration-time Profile of the AQ280 Main Metabolite, AQ282: Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity
NA; 32.7; 43.7; 45.1; 239; 210 0.4600
SECONDARY
Part A (SAD) - Primary PK Parameter Derived From Plasma Concentration-time Profile of the AQ280 Main Metabolite, AQ282: Maximum Observed Concentration (Cmax)
0.722; 3.38; 3.91; 3.84; 24.4; 24.4 0.2350
SECONDARY
Part A (SAD) - Difference in Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity in Fasted State and in Fed State
539; 527
SECONDARY
Part A (SAD) - Difference in Maximum Observed Concentration (Cmax) in Fasted State and in Fed State
113; 90.8
SECONDARY
Part B (MAD) - Primary PK Parameters Derived From Plasma Concentration-time Profile of AQ280: Accumulation Ratio (AR)
1.13; 1.03; 1.12; 1.11; 0.910; 1.12
SECONDARY
Part B (MAD) - Primary PK Parameters Derived From Plasma Concentration-time Profile of AQ280: Area Under the Concentration Time Curve Over a Dosing Interval
300; 978; 2910; 345; 1000; 3150 0.1558
SECONDARY
Part B (MAD) - Primary PK Parameters Derived From Plasma Concentration-time Profile of AQ280: Maximum Observed Concentration (Cmax)
64.5; 248; 560; 72.0; 226; 590 0.5458
SECONDARY
Part B (MAD) - Primary PK Parameter Derived From Plasma Concentration-time Profile of the AQ280 Main Metabolite, AQ282: Area Under the Concentration Time Curve Over a Dosing Interval (AUCτ)
31.3; 121; 217; 37.0; 123; 214 0.4856
SECONDARY
Part B (MAD) - Primary PK Parameter Derived From Plasma Concentration-time Profile of the AQ280 Main Metabolite, AQ282: Maximum Observed Concentration (Cmax)
3.37; 15.6; 24.6; 3.59; 14.2; 21.3 0.1455

Summary

The principal aim of this study is to obtain safety and tolerability data when AQ280 is administered orally as single and multiple doses to healthy subjects. This information, together with the pharmacokinetic (PK) data, will help establish the doses and dosing regimen suitable for future studies in patients.

Eligibility Criteria

Inclusion Criteria

Subjects must satisfy all of the following criteria at the screening visit (and/or at check-in, where noted):

  • Males or females, of any race, between 18 and 65 years of age, inclusive.
  • Body mass index between 18.0 and 32.0 kg/m2, inclusive.
  • In good health, determined by no clinically significant findings from medical history, 12 lead ECG, vital sign measurements, and clinical laboratory evaluations at screening and check-in and from the physical examination at check-in, as assessed by the investigator (or designee).
  • Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception.
  • Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions.

Exclusion Criteria

Subjects will be excluded from the study if they satisfy any of the following criteria at the screening visit (or at check-in, where noted):

Medical conditions

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
  • History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee).
  • History of any surgical (eg, stomach or intestinal surgery or resection) or medical condition that would potentially alter absorption, distribution, metabolism, and/or excretion of orally administered drugs. Uncomplicated appendectomy and hernia repair will be allowed. Cholecystectomy will not be allowed.
  • History of any significant infectious disease, as assessed by the investigator, within 2 weeks prior to the first dose of IMP.
  • Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) values >1.2 × upper limit of normal (ULN).
  • Congenital nonhemolytic hyperbilirubinemia (including suspicion of Gilbert's syndrome).
  • Hemoglobin value, neutrophil count, and/or lymphocyte count 21 units per week for males and >14 units for females. One unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits.
  • Positive alcohol breath test result or positive urine drug screen (confirmed by repeat) at screening or check-in.
  • History of alcoholism or drug/chemical abuse within 2 years prior to check-in.
  • Smoking >5 cigarettes per day, on average, or use the equivalent tobacco- or nicotine containing products per day.
  • Ingestion of poppy seed , Seville orange , star fruit-, or grapefruit containing foods or beverages within 7 days prior to check-in.

Other exclusions

  • Receipt of blood products within 2 months prior to check-in.
  • Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to screening, or platelets from 6 weeks prior to screening.
  • Poor peripheral venous access.
  • Subjects who, in the opinion of the investigator (or designee), should not participate in this study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05485779). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search